1. Search Result
Search Result
Isoforms Recommended: Oxazolidinone
Results for "

oxazolidinone

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

4

Biochemical Assay Reagents

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W012982

    AOZ

    Drug Metabolite Monoamine Oxidase Cardiovascular Disease Metabolic Disease
    3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo. 3-Amino-2-oxazolidinone is orally active .
    3-Amino-2-oxazolidinone
  • HY-W002062

    Biochemical Assay Reagents Others
    (S)-4-Isopropyl-2-oxazolidinone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Isopropyl-2-oxazolidinone
  • HY-W007664

    Biochemical Assay Reagents Others
    (R)-4-Benzyl-2-oxazolidinone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (R)-4-Benzyl-2-oxazolidinone
  • HY-W012982S

    AOZ-d4

    Drug Metabolite Others
    3-Amino-2-oxazolidinone-d4 is a deuterium labeled 3-Amino-2-oxazolidinone. 3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as an indicator of furazolidone residues[1][2].
    3-Amino-2-oxazolidinone-d4
  • HY-41882

    (-)-4-Benzyl-2-oxazolidinone

    Biochemical Assay Reagents Others
    (S)-4-Benzyl-2-oxazolidinone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Benzyl-2-oxazolidone
  • HY-135397

    (R)-PNU-100766

    Drug Metabolite Infection
    (R)-Linezolid is an impurity of Linezolid (PNU-100766). Linezolid, the first member of the class of oxazolidinone synthetic antibiotic, acts by inhibiting the initiation of bacterial protein synthesis .
    (R)-​Linezolid
  • HY-139398
    TBI-223
    1 Publications Verification

    Antibiotic Bacterial Infection
    TBI-223 is an orally bioavailable oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb) .
    TBI-223
  • HY-W012982R

    Drug Metabolite Metabolic Disease
    3-Amino-2-oxazolidinone (Standard) is the analytical standard of 3-Amino-2-oxazolidinone. This product is intended for research and analytical applications. 3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo .
    3-Amino-2-oxazolidinone (Standard)
  • HY-167892

    Antibiotic Bacterial Infection Inflammation/Immunology
    DRF-8417, an oxazolidinone antibiotic, is active against Gram-positive and fastidious Gram-negative bacteria. DRF 8417 exhibits potent activity against Gram-positive pathogens with MIC50 and MIC90 values ranging from 0.06 to 1 mg/L .
    DRF-8417
  • HY-138181

    MRX-I phosphoramidic acid

    Drug Intermediate Others
    Contezolid phosphoramidic acid is an intermediate in the synthesis of proagents of antibacterial oxazolidinone agent MRX-I. Contezolid phosphoramidic acid is extracted from patent WO2015127316A1, Intermediate 3, Method I .
    Contezolid phosphoramidic acid
  • HY-135397R

    Drug Metabolite Infection
    (R)-​Linezolid (Standard) is the analytical standard of (R)-​Linezolid. This product is intended for research and analytical applications. (R)-Linezolid is an impurity of Linezolid (PNU-100766). Linezolid, the first member of the class of oxazolidinone synthetic antibiotic, acts by inhibiting the initiation of bacterial protein synthesis .
    (R)-​Linezolid (Standard)
  • HY-15993

    AZD2563; AZD5847

    Antibiotic Infection
    Posizolid (AZD2563), an oxazolidinone antibiotic, is developed by AstraZeneca for the study of bacterial infections. Posizolid shows very good anti-mycobacterial activity .
    Posizolid
  • HY-10392
    Sutezolid
    4 Publications Verification

    PNU-100480; U-100480; PF-02341272

    Bacterial Antibiotic Infection
    Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
    Sutezolid
  • HY-10392R

    PNU-100480 (Standard); U-100480 (Standard); PF-02341272 (Standard)

    Bacterial Antibiotic Infection
    Sutezolid (Standard) is the analytical standard of Sutezolid. This product is intended for research and analytical applications. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis[1][2].
    Sutezolid (Standard)
  • HY-167841

    Bacterial Antibiotic Infection
    Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors,including Vancomycin (HY-B0671),aminoglycoside/Tetracycline (HY-A0107),and oxazolidinone resistance .
    Anti-MRSA agent 19
  • HY-101818

    Antibiotic Bacterial Infection
    PNU288034 is a potent oxazolidinone antibiotic.
    PNU288034
  • HY-125074

    Antibiotic Infection
    PNU 142300 is an inactive metabolite of the oxazolidinone antibiotic Linezolid (HY-10394).
    PNU 142300
  • HY-100436

    ACT-179811

    Bacterial Antibiotic Infection
    Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid
  • HY-101819

    Bacterial Infection
    Antibacterial compound 1 is a oxazolidinone extracted from patent WO1999037630A1 with antibacterial activities.
    Antibacterial compound 1
  • HY-101726

    Bacterial Antibiotic Infection
    DuP 105 is an orally active oxazolidinone, a new class of synthetic antimicrobial agent with activity against gram-positive bacteria.
    DuP 105
  • HY-111056

    Ser/Thr Protease Cancer
    UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
    UK122
  • HY-14855A
    (S)-Tedizolid
    2 Publications Verification

    (S)-TR 700; (S)-DA 7157

    Bacterial Antibiotic Infection
    (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
    (S)-Tedizolid
  • HY-100180
    Delpazolid
    1 Publications Verification

    LCB01-0371

    Bacterial Antibiotic Infection
    Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them.
    Delpazolid
  • HY-W019727

    (S)-(+)-4-Phenyl-2-oxazolidinone

    Biochemical Assay Reagents Others
    (S)-4-Phenyloxazolidin-2-one is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Phenyloxazolidin-2-one
  • HY-122123

    Bacterial Antibiotic Infection
    S-6123 is a potent antimicrobial compound of the oxazolidinone series. S-6123 inhibits ribosomal protein synthesis without inhibiting DNA or RNA synthesis .
    S-6123
  • HY-14800
    Radezolid
    5+ Cited Publications

    RX-1741

    Bacterial Antibiotic Infection
    Radezolid (RX-1741) is a oxazolidinone antibiotic. Radezolid is active against Staphylococcus, Chlamydia, and Legionella species, and remains active against Linezolid-resistant strains .
    Radezolid
  • HY-100436R

    ACT-179811 (Standard)

    Bacterial Antibiotic Infection
    Cadazolid (Standard) is the analytical standard of Cadazolid. This product is intended for research and analytical applications. Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid (Standard)
  • HY-14855
    Tedizolid
    10+ Cited Publications

    TR 700; Torezolid; DA-7157

    Bacterial Antibiotic Infection
    Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid
  • HY-113687

    Bacterial Infection
    T145 is an oxazolidinone with antibacterial activity that inhibits growth of gram negatives (K. pneumoniae, A. baumannii, P. aeruginosa and E. cloacae), gram positives (E. faecalis and S. aureus) and acid fast pathogens (Mab, Mav and Mtb) .
    T145
  • HY-14855AR

    (S)-TR 700 (Standard); (S)-DA 7157 (Standard)

    Bacterial Antibiotic Infection
    (S)-Tedizolid (Standard) is the analytical standard of (S)-Tedizolid. This product is intended for research and analytical applications. (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
    (S)-Tedizolid (Standard)
  • HY-19915A

    MRX-4

    Bacterial Antibiotic Infection Inflammation/Immunology
    Contezolid acefosamil (MRX-4) is the orally active proagent of the active antimicrobial metabolite Contezolid (MRX-I), an oxazolidinone which shows potent in vitro activity against various multidrug-resistant Gram-positive bacteria, including MRSA .
    Contezolid acefosamil
  • HY-14800R

    RX-1741 (Standard)

    Bacterial Antibiotic Infection
    Radezolid (Standard) is the analytical standard of Radezolid. This product is intended for research and analytical applications. Radezolid (RX-1741) is a oxazolidinone antibiotic. Radezolid is active against Staphylococcus, Chlamydia, and Legionella species, and remains active against Linezolid-resistant strains[1][2].
    Radezolid (Standard)
  • HY-19915
    Contezolid
    2 Publications Verification

    MRX-I

    Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid
  • HY-10394
    Linezolid
    Maximum Cited Publications
    34 Publications Verification

    PNU-100766

    Bacterial Antibiotic Infection Cancer
    Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    Linezolid
  • HY-14855R

    Bacterial Antibiotic Infection
    Tedizolid (Standard) is the analytical standard of Tedizolid. This product is intended for research and analytical applications. Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid (Standard)
  • HY-163486

    Bacterial Infection
    Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .
    Antituberculosis agent-10
  • HY-19915B

    MRX-4 sodium

    Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid acefosamil sodium
  • HY-14855S

    TR 700-13C,d3; Torezolid-13C,d3; DA-7157-13C,d3

    Isotope-Labeled Compounds Bacterial Antibiotic Infection
    Tedizolid- 13C,d3 is the 13C- and deuterium labeled Tedizolid. Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid-13C,d3
  • HY-10392S

    PNU-100480-13C4; U-100480-13C4; PF-02341272-13C4

    Isotope-Labeled Compounds Antibiotic Bacterial Infection
    Sutezolid- 13C4 (PNU-100480- 13C4) is 13C labeled Sutezolid. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
    Sutezolid-13C4
  • HY-10394R

    PNU-100766 (Standard)

    Bacterial Antibiotic Infection
    Linezolid (Standard) is the analytical standard of Linezolid. This product is intended for research and analytical applications. Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    Linezolid (Standard)
  • HY-10394S1

    PNU-100766-d8

    Antibiotic Bacterial Isotope-Labeled Compounds Infection
    PNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    PNU-100766-d8
  • HY-160761

    Opioid Receptor Inflammation/Immunology
    K-Opioid receptor agonist-1 (Compound 5a) is an agonist for κ-Opioid receptor with Ki of 0.25 nM and EC50 of 2 nM. K-Opioid receptor agonist-1 is blood brain barrier (BBB) penetrate (brain/plasma ratios of 0.50 to 0.65). K-Opioid receptor agonist-1 exhibits anti-inflammatory activity in dermatitis models induced by Arachidonic acid (HY-109590) or oxazolidinone .
    K-Opioid receptor agonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: